Look back at pharma news in week to Jan 19

21 January 2018

By Barbara Obstoj-Cardwell. Editor

Regulatory decisions from the US Food and Drug Administration featured in the news last with, with a negative advisory panel vote on Aradigm’s antibiotic candidate Linhaliq and news of acceptance of a Biologicals License Application for a Humira (adalimumab) by Novartis subsidiary Sandoz. On the research front, Eiger BioPharmaceutical’s pulmonary arterial hypertension drug ubenimex failed. There was strong speculation that Celgene was planning a takeover bid for CAR-T cell therapy specialist Juno Pharma. Also there was disappointment for Johnson & Johnson with the revocation of Johnson & Johnson’s Zytiga patent.

Aradigm gets voted down by FDA panel for antibiotic drug

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK